• Register
X
Forgot Password

If you have forgotten your password you can enter your email here and get a temporary password sent to your email.

X

Leaving Community

Are you sure you want to leave this community? Leaving the community will revoke any permissions you have been granted in this community.

No
Yes

TACI is a TRAF-interacting receptor for TALL-1, a tumor necrosis factor family member involved in B cell regulation.

We and others recently reported tumor necrosis factor (TNF) and apoptosis ligand-related leukocyte-expressed ligand 1 (TALL-1) as a novel member of the TNF ligand family that is functionally involved in B cell proliferation. Transgenic mice overexpressing TALL-1 have severe B cell hyperplasia and lupus-like autoimmune disease. Here, we describe expression cloning of a cell surface receptor for TALL-1 from a human Burkitt's lymphoma RAJI cell library. The cloned receptor is identical to the previously reported TNF receptor (TNFR) homologue transmembrane activator and calcium modulator and cyclophilin ligand (CAML) interactor (TACI). Murine TACI was subsequently isolated from the mouse B lymphoma A20 cells. Human and murine TACI share 54% identity overall. Human TACI exhibits high binding affinities to both human and murine TALL-1. Soluble TACI extracellular domain protein specifically blocks TALL-1-mediated B cell proliferation without affecting CD40- or lipopolysaccharide-mediated B cell proliferation in vitro. In addition, when injected into mice, soluble TACI inhibits antibody production to both T cell-dependent and -independent antigens. By yeast two-hybrid screening of a B cell library with TACI intracellular domain, we identified that, like many other TNFR family members, TACI intracellular domain interacts with TNFR-associated factor (TRAF)2, 5, and 6. Correspondingly, TACI activation in a B cell line results in nuclear factor kappaB and c-Jun NH(2)-terminal kinase activation. The identification and characterization of the receptor for TALL-1 provides useful information for the development of a treatment for B cell-mediated autoimmune diseases such as systemic lupus erythematosus.

Pubmed ID: 10880535

Authors

  • Xia XZ
  • Treanor J
  • Senaldi G
  • Khare SD
  • Boone T
  • Kelley M
  • Theill LE
  • Colombero A
  • Solovyev I
  • Lee F
  • McCabe S
  • Elliott R
  • Miner K
  • Hawkins N
  • Guo J
  • Stolina M
  • Yu G
  • Wang J
  • Delaney J
  • Meng SY
  • Boyle WJ
  • Hsu H

Journal

The Journal of experimental medicine

Publication Data

July 3, 2000

Associated Grants

None

Mesh Terms

  • Amino Acid Sequence
  • Animals
  • B-Cell Activating Factor
  • B-Lymphocytes
  • Burkitt Lymphoma
  • CD4-Positive T-Lymphocytes
  • CD8-Positive T-Lymphocytes
  • Gene Library
  • Humans
  • Ligands
  • Lymphocyte Activation
  • Lymphoma, B-Cell
  • Membrane Proteins
  • Mice
  • Molecular Sequence Data
  • Receptors, Tumor Necrosis Factor
  • Sequence Alignment
  • Sequence Homology, Amino Acid
  • Transmembrane Activator and CAML Interactor Protein
  • Tumor Cells, Cultured
  • Tumor Necrosis Factor-alpha